论文部分内容阅读
使用精蛋白锌重组赖脯胰岛素混合注射液(25R)胰岛素每天2次皮下注射治疗2型糖尿病患者23例。行16周优泌乐25每天2次皮下注射治疗,16后后糖化血红蛋白测定,然后注射精蛋白锌重组赖脯胰岛素混合注射液(50R)替换治疗16周,16周后进行糖化血红蛋白测定。比较2种胰岛素疗效与低血糖发生率。结果:观察前后两种治疗方法FBG、2hFBG、HbA_1c、低血糖发生率及胰岛素用量变化。结果:两种胰岛素治疗后2hFBG、HbA1c差异有显著性(P<0.05),优泌乐50组在2hFBG控制及HbA1c达标上优于优泌乐25组。在FBG、低血糖发生率及胰岛素用量比较,两组差异无显著性(P>0.05),结论应用优泌乐50治疗2型糖尿病治疗中对2hFBG、HbA_1c控制优于优泌乐25,有利于血糖控制全面达标。对糖尿病性并发症的预防更意义,比较适合于中国糖尿病患者。
Twenty-three patients with type 2 diabetes were treated subcutaneously twice a day with protamine zinc-conjugated insulin lispro mixed injection (25R). Sixteen patients were treated with subcutaneous gavage twice a day for 16 weeks and 16 after glycosylated hemoglobin determination. The patients were then treated with protamine-zinc-conjugated insulin lispro injection (50R) for 16 weeks. HbA1c was measured after 16 weeks. Compare two kinds of insulin curative effect and incidence of hypoglycemia. Results: The changes of FBG, 2h FBG, HbA 1c, incidence of hypoglycemia and insulin dosage before and after treatment were observed. Results: The difference of FBG and HbA1c was significant at 2h after two kinds of insulin treatment (P <0.05). Ershi-Le 50 group was superior to Gucre-Le 25 in 2hFBG control and HbA1c compliance. There was no significant difference between the two groups in the incidence of FBG, hypoglycemia and insulin dosage (P> 0.05) .Conclusion The control of 2hFBG and HbA_1c in the treatment of type 2 diabetes mellitus is superior to that of Gucre-25 in the treatment of type 2 diabetes mellitus, Blood glucose control a full compliance. Prevention of diabetic complications more meaningful, more suitable for Chinese patients with diabetes.